Previous 10 | Next 10 |
Nevro (NVRO) has submitted a pre-market approval supplement to the FDA seeking approval of its Senza System for the treatment of chronic pain associated with Painful Diabetic Neuropathy ((PDN)). This submission, assuming a six-month review cycle, would position the company to achieve FDA appr...
Nevro Announces FDA Submission for HF10® Therapy in Patients with Painful Diabetic Neuropathy SENZA-PDN Study is Largest Prospective, Multicenter, Randomized Clinical Trial of Spinal Cord Stimulation Conducted to Date PR Newswire REDWOOD CITY, Calif. , Dec...
Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference Friday, January 15, 2021, at 4:00 pm Pacific Time / 6:00 pm Central Time PR Newswire REDWOOD CITY, Calif. , Dec. 22, 2020 /PRNewswire/ -- Nev...
Nevro has been prospering in its chosen specialty of opioid-free pain relief. Nevro's Omnia launch has been dampened by the pandemic; expect good things as the pandemic moves to the rear. Painful diabetic neuropathy will provide an important new market for Nevro to develop. Ne...
Nevro to Present at 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 REDWOOD CITY, Calif. , Dec. 15, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for t...
Nevro ([[NVRO]] +5.3%) has agreed to dismiss its patent case against with Boston Scientific ([[BSX]] +3.7%) relating to high- frequency spinal cord stimulation ((SCS)) therapy. The patent case began in late 2016 when Nevro accused Boston Scientific of infringing patents related to its Senza s...
Boston Scientific Announces Stipulation Of Dismissal Of Nevro Corporation's Patent Infringement Case In California MARLBOROUGH, Mass. , Dec. 14, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that a stipulation of dismissal has been filed ...
Nevro Announces Agreement to Conclude Its Patent Lawsuit in the Northern District of California Against Boston Scientific REDWOOD CITY, Calif. , Dec. 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative,...
Nevro Announces Director Appointment REDWOOD CITY, Calif. , Dec. 3, 2020 /PRNewswire/ -- Nevro Corp. ( " Nevro") (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, ann...
Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications PR Newswire REDWOOD CITY, Calif., Nov. 30, 2020 REDWOOD CITY, Calif. , Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device c...
News, Short Squeeze, Breakout and More Instantly...
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024 PR Newswire REDWOOD CITY, Calif. , July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-chan...
Nevro to Present at Truist Securities MedTech Conference PR Newswire REDWOOD CITY, Calif. , June 11 , 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chr...
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 PR Newswire REDWOOD CITY, Calif. , May 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the trea...